Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
The legal team said the jury's decision could make medics think twice before allowing the injured to return to the field.
Read Full NewsThe pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.
Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.
Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO
1.
Ketamine plus psychotherapy for "excellent" PTSD
2.
New imaging guidelines for head and neck cancers, a step toward practice change
3.
Scientists develop scans that light up aggressive cancer tumors for better treatment
4.
Higher levels of HIF2α found to slow down aggressive childhood cancer
5.
Fighting for others: How guilt and obligation drive desire for more intensive treatments in end-of-life cancer care
1.
Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer
2.
Fresh Frozen Plasma: Its Role in Treating Trauma and Bleeding Disorders
3.
The Importance of Understanding Carboxyhemoglobin Levels in the Body: A Comprehensive Guide
4.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
5.
Screening Strategies in Oncology: A Subspecialty Guide to Early Detection and Better Outcomes
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
2.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
3.
CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
5.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge